title: Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
abstract: OBJECTIVE
  This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting.
  
  
  METHODS
  We consecutively recruited 100 schizophrenia patients and assessed clinical improvement after 4 weeks of risperidone treatment.
  
  
  RESULTS
  The patients with T/T in the HTR2A gene showed less clinical improvement than did those with T/C or C/C (p = 0.044). In the case of the DRD3 gene, we did not find statically significant association with clinical improvement (p = 0.061). When patients were categorized into responders and nonresponders, the C allele was more frequent in responders (OR = 2.28, 95%CI = 1.06-4.91, p = 0.039). When combinations of the two polymorphisms were considered, patients who had T/T in the HTR2A gene and encoded Ser/Ser or Ser/Gly from DRD3 gene had a higher propensity to non-responsiveness compared to other subjects (OR = 3.57, 95%CI = 1.10-11.62, p = 0.039).
  
  
  CONCLUSIONS
  Our findings suggest that the HTR2A T102C could be a potential indicator of clinical improvement after risperidone treatment.
authors.affiliation: Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Byungsu
authors.initials: B
authors.lastname: Kim
authors.forename: Eui Yul
authors.initials: EY
authors.lastname: Choi
authors.forename: Chang Yoon
authors.initials: CY
authors.lastname: Kim
authors.forename: Kyuyung
authors.initials: K
authors.lastname: Song
authors.forename: Yeon Ho
authors.initials: YH
authors.lastname: Joo
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D005998:Glycine / Q000235:genetics; D006801:Humans; D008297:Male; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011569:Psychiatric Status Rating Scales; D050637:Receptors, Dopamine D3 / Q000235:genetics*; D044348:Receptors, Serotonin, 5-HT2 / Q000235:genetics*; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics; D012694:Serine / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D050637:Receptors, Dopamine D3; D044348:Receptors, Serotonin, 5-HT2; D012694:Serine; D018967:Risperidone; D005998:Glycine